4 results
Primary objective:To determine the safety and tolerability of multiple doses of MOR103 in patients with active rheumatoid arthritis, at ascending dose levels.Secondary objectives:- to evaluate signs of efficacy of MOR103 in patients with active…
To establish the safety, tolerability, and early efficacy of multiple doses of hLF1-11 given once daily for 14 days.
Primary objective adults:To demonstrate the superiority of iptacopan (200 mg b.i.d.) compared to placebo in reducing proteinuria at 6 months of treatment.The primary clinical question of interest is:What is the effect of iptacopan vs. placebo on log…
The purpose of the study is to evaluate the efficacy and safety of LNP023 compared to placebo on proteinuria reduction and slowing renal disease progression in primary IgAN patients